Replicate Bioscience is a technology company.
Replicate Bioscience has raised $40.0M across 1 funding round.
Replicate Bioscience has raised $40.0M in total across 1 funding round.
Replicate Bioscience has raised $40.0M in total across 1 funding round.
Replicate Bioscience's investors include Michael Ehlers, Seth L. Harrison, Spiros Liras, ATP (Apple Tree Partners).
Replicate Bioscience is a clinical-stage biotechnology company developing self-replicating RNA (srRNA) therapeutics to overcome limitations of conventional RNA approaches, enabling higher protein expression, greater durability, and improved therapeutic index for diseases like cancer, autoimmune disorders, infectious diseases, and cardiometabolic conditions.[1][2][3] The company builds a proprietary srRNA platform using synthetic biology and virally derived vectors that harness cells' natural protein production machinery, serving patients with drug-resistant cancers, inflammatory diseases, obesity, diabetes, and more, while solving key challenges like low potency and short duration of existing mRNA therapies.[1][2][5] Growth momentum includes Phase 1 data for its lead rabies vaccine RBI-4000 showing protective immunity at ultra-low doses, a partnership with Novo Nordisk for obesity and diabetes treatments, a recent collaboration with Instituto Butantan for rabies vaccine commercialization in Latin America, $40 million Series A funding in 2021, and ongoing preclinical candidates across multiple areas.[2][4][5]
Replicate Bioscience originated in 2014 when co-founders Nathaniel Wang, Ph.D., and Andy Geall, Ph.D., both veterans in RNA vaccine development, posed the question: "If we wanted to create the best self-replicating RNA platform from scratch, how would we do it?"[3] They were later joined by Herbert Kim Lyerly, M.D., and Zachary Hartman, Ph.D., professors of cancer research and immunology at Duke University, shifting focus to srRNA for preventing drug-resistant cancer mutations; the company exclusively licensed Duke's technology and built new vectors from scratch.[3][4] Pivotal early traction came with $40 million in Series A funding from ATP in September 2021 to advance srRNA programs into clinical development, followed by rapid progress to clinical-stage assets like RBI-4000 and partnerships with industry leaders.[2][4]
Replicate stands out in RNA therapeutics through these key advantages:
Replicate rides the explosive growth of RNA therapeutics post-mRNA vaccines, addressing critical pain points like transient expression and immunogenicity to expand applications beyond vaccines into oncology, autoimmunity, and metabolic diseases.[2][3][5] Timing is ideal amid surging demand for durable, potent biologics—market forces like rising cancer drug resistance, cardiometabolic epidemics, and global infectious threats favor srRNA's advantages in protein output and therapeutic index.[1][2] By licensing academic tech, securing big-pharma deals (e.g., Novo Nordisk), and advancing low-dose vaccines for underserved regions via Butantan, Replicate influences the ecosystem by accelerating srRNA adoption, lowering manufacturing barriers, and enabling scalable treatments that could reach billions.[2][4][5]
Replicate is poised to disrupt RNA therapeutics with its maturing pipeline, recent leadership additions like Chief Business Officer Kathy Fernando, Ph.D., and high-profile collaborations signaling commercial momentum.[5] Upcoming milestones include RBI-4000 Phase 1 durability readouts, Latin American rabies vaccine rollout, and Novo Nordisk-partnered obesity/diabetes programs, potentially yielding first srRNA approvals in vaccines and beyond.[2][5] Trends like AI-optimized vectors, combo therapies for inflammasomes, and global health equity will shape its path, evolving Replicate from a platform innovator to a multi-billion-impact leader in next-gen RNA medicines—amplifying the body's protein power to fight disease at scale.[1][2][3]
Replicate Bioscience has raised $40.0M across 1 funding round. Most recently, it raised $40.0M Series A in September 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2021 | $40.0M Series A | Michael Ehlers, Seth L. Harrison, Spiros Liras, ATP (Apple Tree Partners) |